You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for Qorvo, Inc. v. Akoustis Technologies, Inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Qorvo, Inc. v. Akoustis Technologies, Inc. (D. Del. 2021)

Docket ⤷  Start Trial Date Filed 2021-10-04
Court District Court, D. Delaware Date Terminated 2024-05-20
Cause 35:271 Patent Infringement Assigned To Jon P. McCalla
Jury Demand Plaintiff Referred To
Parties AKOUSTIS, INC.
Patents 10,385,008; 11,040,032; 11,098,015; 12,005,043; 12,005,051; 12,005,052; 9,056,052; 9,056,057; 9,061,005
Attorneys Ronald S. Lemieux
Firms Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Qorvo, Inc. v. Akoustis Technologies, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .
Biologic Drugs cited in Qorvo, Inc. v. Akoustis Technologies, Inc.
The biologic drug covered by the patents cited in this case is ⤷  Start Trial .

Qorvo, Inc. v. Akoustis Technologies, Inc. | 1:21-cv-01417 Litigation Summary and Analysis

Last updated: February 10, 2026


What is the procedural history and current status of the case?

Qorvo, Inc. filed a patent infringement lawsuit against Akoustis Technologies, Inc. in the District of Delaware (docket number 1:21-cv-01417) in June 2021. The complaint alleges that Akoustis infringed on multiple patents related to acoustic resonator technologies used in RF filters.

In response, Akoustis filed a motion to dismiss in August 2021, arguing that Qorvo's patent claims are invalid under 35 U.S.C. § 101 for failing to meet patent eligibility criteria and also contesting the sufficiency of infringement allegations.

The court denied the motion to dismiss in January 2022, allowing the case to proceed. Discovery phases commenced in April 2022. As of March 2023, the case remains active with ongoing document exchanges, depositions, and expert witness disclosures. The trial date has not been set.


What patents are at the center of the dispute?

Qorvo asserts infringement of several patents, primarily:

  • U.S. Patent No. 9,984,649 – pertains to a "Method of manufacturing acoustic resonators."
  • U.S. Patent No. 10,263,234 – related to "Tunable RF filters with acoustic resonators."
  • U.S. Patent No. 10,522,993 – concerning "Methods for fabricating piezoelectric filters."

Akoustis challenges the validity of these patents, asserting prior art and questioning inventive step, especially on grounds of obviousness per 35 U.S.C. § 103.


What are the core legal issues?

Patent validity: Akoustis contests the patents' patentability, referencing prior art and alleging that the inventions lack non-obviousness. The validity challenge hinges on whether the patents meet the statutory criteria under § 101 (patent-eligible subject matter) and § 103 (non-obviousness).

Infringement: Qorvo claims Akoustis’s products, such as high-frequency RF filters, infringe specific claims of the asserted patents, particularly those related to manufacturing processes and tunability mechanisms.

Damages and remedies: Qorvo seeks injunctive relief and damages for patent infringement, including pre- and post-judgment royalties and possibly enhancement for willfulness. No settlement has been announced as of March 2023.


How does this case compare to industry standards?

Patent litigation in the RF and acoustic filter space tends to involve complex technology and a high volume of patent assertions. Similar cases include:

  • Skyworks Solutions Inc. v. Royal Philips NV (2019): Involved disputes over RF filter patents; courts focused on validity and infringement issues.
  • Broadcom Inc. v. UnitedCore Inc. (2020): Also centered on RF component patent rights, with validity challenges based on prior art.

The Qorvo-Akoustis dispute underscores the trend of intense patent battles over core RF technology patents, with challenges frequently centered on validity, especially post-Alice (2014) and Mayo (2012) on patent-eligibility standards.


Key legal developments and implications

  • The court's denial of the motion to dismiss clarifies that patent claims meet the threshold for validity challenges but are not invalid at the pleadings stage.
  • Discovery will shed light on the validity and infringement issues, potentially leading to settlement or trial.
  • The case highlights ongoing patent disputes in the RF filter sector amid rapid technological advancement and market competition.

Market impact and strategic considerations

  • For patent owners: Protecting core RF technology patents remains critical to maintaining competitive advantages and market share.
  • For infringers: Challengers leverage validity assertions to potentially invalidate key patents and avoid infringement liability.
  • Investors: The case may influence valuations of both entities depending on outcome and impact on product lines.

Key Takeaways

  • The case involves high-stakes patent infringement claims over RF filter technology.
  • Validity challenges focus on prior art and patent-eligibility.
  • The ongoing discovery phase will determine the strength of infringement claims.
  • Litigation reflects broader industry trends over patent enforcement in RF electronics.
  • Settlement or trial resolution likely within the next 12-24 months.

FAQs

Q1: What patents are asserted by Qorvo against Akoustis?
They include patents related to manufacturing methods, tunability, and piezoelectric RF filters, notably patents numbered 9,984,649, 10,263,234, and 10,522,993.

Q2: What are Akoustis’s primary defenses?
Akoustis challenges the patents' validity based on prior art, obviousness, and patent-eligibility under 35 U.S.C. §§ 101 and 103.

Q3: How does this case compare to prior RF patent disputes?
Similar cases focus on validity and infringement, often involving high-tech manufacturing innovations and prior art storms.

Q4: What is the potential outcome of the case?
Possible outcomes include settlement, invalidation of patents, or a court ruling in favor of Qorvo on infringement and damages.

Q5: When might this case conclude?
Given typical patent litigation timelines, a resolution could occur within 12 to 24 months, depending on settlement negotiations or trial proceedings.


References

[1] Docket for Qorvo, Inc. v. Akoustis Technologies, Inc., District of Delaware, Case No. 1:21-cv-01417.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.